The Latest Breaking News from Alnylam Pharmaceuticals

A Relative Strength Rating upgrade for Alnylam Pharmaceuticals shows improving technical performance. Will it continue?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q4 sales of $258.54 million. Earnings fell to a loss of $258.46 million, resulting in a 26.38% decrease from last quarter.

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

  Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q4 earnings results on Thursday, February 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

If history is any guide, there may be trouble ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.